Autoinjector Market Report by Type (Disposable Autoinjectors, Reusable Autoinjectors), Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, and Others), End User (Home Care Settings, Hospitals and Clinics), and Region 2024-2032

Autoinjector Market Report by Type (Disposable Autoinjectors, Reusable Autoinjectors), Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, and Others), End User (Home Care Settings, Hospitals and Clinics), and Region 2024-2032


The global autoinjector market market size reached US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2032, exhibiting a growth rate (CAGR) of 13.9% during 2024-2032.

Autoinjectors are self-injectable devices that help deliver drugs via the subcutaneous or intramuscular route. They offer several advantages, such as dosage accuracy and improved patient compliance, and help reduce needle phobia of patients, lower needlestick injuries resulting from a hidden needle, and increase the convenience and efficiency of healthcare professionals. They are widely used during emergency conditions, such as anaphylaxis, migraine, status epilepticus, psoriasis, diabetes, multiple sclerosis, and rheumatoid arthritis. As a result, autoinjectors find extensive applications in hospitals, clinics, and home care centers across the globe.

Autoinjector Market Trends:
At present, there is a rise in the prevalence of arthritis, asthma, cancer, chronic obstructive pulmonary disease (COPD) and Alzheimer’s disease. This, along with the growing need for self-administrating medicines, represents one of the key factors driving the market. Moreover, governments of several countries are undertaking initiatives to promote the use of autoinjectors in schools. This, coupled with the increasing awareness among individuals about the benefits of autoinjectors, is propelling the growth of the market. In addition, key market players are extensively investing in research and development (R&D) activities to develop simple, cost-effective, and new technology-based autoinjectors for treating rheumatoid arthritis and multiple sclerosis. Besides this, the rising adoption of targeted therapies to alter proteins within cancer cells and prevent the formation of new blood vessels in the tumor is offering lucrative growth opportunities to industry investors. Additionally, the burgeoning healthcare industry around the world is bolstering the growth of the market. Some of the other factors inducing growth are the increasing number of regulatory approvals, technological advancements, patent expiry of biologics and the availability of generic versions of autoinjectors.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global autoinjector market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application and end user.

Breakup by Type:

Disposable Autoinjectors
Reusable Autoinjectors

Breakup by Application:

Rheumatoid Arthritis
Anaphylaxis
Multiple Sclerosis
Others

Breakup by End User:

Home Care Settings
Hospitals and Clinics

Breakup by Region:


North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Antares Pharma Inc., Becton Dickinson and Company, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Haselmeier GmbH (Sulzer Ltd.), Johnson & Johnson, Mylan N.V. (Viatris Inc.), Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd. and Ypsomed Holding AG.

Key Questions Answered in This Report

1. What was the size of the global autoinjector market in 2023?
2. What is the expected growth rate of the global autoinjector market during 2024-2032?
3. What are the key factors driving the global autoinjector market?
4. What has been the impact of COVID-19 on the global autoinjector market?
5. What is the breakup of the global autoinjector market based on the type?
6. What is the breakup of the global autoinjector market based on the application?
7. What is the breakup of the global autoinjector market based on the end user?
8. What are the key regions in the global autoinjector market?
9. Who are the key players/companies in the global autoinjector market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Autoinjector Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Disposable Autoinjectors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Reusable Autoinjectors
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Application
7.1 Rheumatoid Arthritis
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Anaphylaxis
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Multiple Sclerosis
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by End User
8.1 Home Care Settings
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Hospitals and Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Amgen Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Antares Pharma Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Becton Dickinson and Company
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Bristol-Myers Squibb Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Eisai Co. Ltd.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Eli Lilly and Company
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Haselmeier GmbH (Sulzer Ltd.)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Johnson & Johnson
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Mylan N.V. (Viatris Inc.)
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Novartis AG
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 SHL Medical AG
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.12 Teva Pharmaceutical Industries Ltd.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis
14.3.13 Ypsomed Holding AG
14.3.13.1 Company Overview
14.3.13.2 Product Portfolio
14.3.13.3 Financials
14.3.13.4 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings